ストックスクリーナーアプリを入手
40.75
1.22%
0.51
前日終値:
$40.24
開ける：
$39.82
24時間の取引高:
296.16K
Relative Volume:
0.10
時価総額：
$6.27B
収益：
-
当期純損益:
$-284.08M
株価収益率:
-16.82
EPS:
-2.4234
ネットキャッシュフロー:
$-234.65M
1週間 パフォーマンス:
+5.71%
1か月 パフォーマンス:
+21.44%
6か月 パフォーマンス:
+443.79%
1年 パフォーマンス:
+393.10%
1日の値動き範囲:
$39.37
$40.92
1週間の範囲:
$37.86
$42.25
52週間の値動き範囲:
$3.72
$43.73
Cogent Biosciences Inc Stock (COGT) Company Profile
COGT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
COGT
Cogent Biosciences Inc
|
40.85 | 6.18B | 0 | -284.08M | -234.65M | -2.4234 |
|
VRTX
Vertex Pharmaceuticals Inc
|
454.94 | 115.62B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
747.99 | 79.10B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
851.35 | 52.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.59 | 51.72B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
200.49 | 42.00B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cogent Biosciences Inc Stock (COGT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-10 | アップグレード | Stifel | Hold → Buy |
| 2025-11-10 | アップグレード | Wedbush | Neutral → Outperform |
| 2025-10-16 | 開始されました | Stifel | Hold |
| 2025-09-03 | 開始されました | Raymond James | Strong Buy |
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2024-12-11 | ダウングレード | Needham | Buy → Hold |
| 2024-02-26 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2024-02-08 | 開始されました | Citigroup | Buy |
| 2023-12-11 | ダウングレード | Wedbush | Outperform → Neutral |
| 2023-12-08 | 開始されました | JP Morgan | Overweight |
| 2023-04-28 | 開始されました | Robert W. Baird | Outperform |
| 2023-03-27 | 再開されました | H.C. Wainwright | Buy |
| 2022-12-14 | 開始されました | Needham | Buy |
| 2022-06-28 | 開始されました | Guggenheim | Buy |
| 2021-10-11 | 開始されました | H.C. Wainwright | Buy |
| 2021-06-09 | 再開されました | Jefferies | Buy |
| 2020-12-23 | 開始されました | Piper Sandler | Overweight |
| 2020-10-14 | 開始されました | Ladenburg Thalmann | Buy |
すべてを表示
Cogent Biosciences Inc (COGT) 最新ニュース
Cogent Biosciences: Time For A Pause (NASDAQ:COGT) - Seeking Alpha
Cogent Biosciences Stock Surged by Positive Pivotal Trial Results - StocksToTrade
Cogent Biosciences’ Clinical Trials Propel Stock with Promising Data - timothysykes.com
Frazier Life Sciences Management L.P. Grows Stake in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences prices equity offering and 1.625% convertible senior notes - MSN
Cogent Biosciences’ Stock Climbs with Landmark Clinical Trial Results - StocksToTrade
The Technical Signals Behind (COGT) That Institutions Follow - news.stocktradersdaily.com
Cogent Biosciences Stock Soars on Positive Trial Results - timothysykes.com
Birchview Capital LP Buys New Stake in Cogent Biosciences, Inc. $COGT - MarketBeat
COGT Boom: Is It Time to Cash In? - StocksToTrade
Redmile Group LLC Sells 1,767,986 Shares of Cogent Biosciences, Inc. $COGT - MarketBeat
Will Rising Interest Rates Hurt Piramal Pharma Limiteds Profit MarginsHead and Shoulders Patterns & Access Free Tools and Start Investing - earlytimes.in
Cogent Biosciences (COGT): Valuation Check After Positive APEX Part 2 Trial Results for Bezuclastinib - Sahm
Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis - Investing News Network
Cogent Biosciences stock hits all-time high at 43.07 USD By Investing.com - Investing.com Canada
Cogent Biosciences Presents Positive Clinical Trial Results - TradingView — Track All Markets
Cogent Biosciences (NASDAQ:COGT) Given "Hold" Rating at Needham & Company LLC - MarketBeat
Cogent Biosciences (COGT) Receives 'Hold' Rating from Needham | - GuruFocus
Cogent Biosciences (NASDAQ:COGT) Reaches New 1-Year HighHere's What Happened - MarketBeat
Wedbush Adjusts Cogent Biosciences Price Target to $55 From $38, Maintains Outperform Rating - marketscreener.com
Cogent Biosciences Says Bezuclastinib Showed 'Rapid and Deep Clinical Benefit' in Advanced Systemic Mastocytosis Trial - marketscreener.com
Cogent Biosciences stock hits all-time high at 43.07 USD - Investing.com
Cogent Biosciences : COGT ASH 2025 Webcast FINAL - marketscreener.com
Cogent Biosciences (COGT) Reports Positive Results from APEX Par - GuruFocus
Cogent Biosciences Reports Positive APEX Trial Results for Bezuclastinib in Advanced Systemic Mastocytosis, Plans NDA Submission in 2026 - Quiver Quantitative
Cogent Biosciences announces positive top-line results of apex trial of bezuclastinib in patients with advanced systemic mastocytosis - marketscreener.com
Cogent Biosciences Announces Positive Top-Line Results Of APEX Trial Of Bezuclastinib In Patients With Advanced Systemic Mastocytosis - TradingView — Track All Markets
Cogent Biosciences, Inc. Announces Positive Top-Line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis - marketscreener.com
Schroder Investment Management Group Invests $896,000 in Cogent Biosciences, Inc. $COGT - MarketBeat
Bollard Group LLC Buys New Position in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences' (COGT) Bezuclastinib Shows Promising Results in Clinical Trial - GuruFocus
Cogent Biosciences, Inc. $COGT Shares Purchased by Kennedy Capital Management LLC - MarketBeat
Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis at the 67th Annual Meeting of the American Society of Hematology - Investing News Network
Cogent Biosciences Reports Positive Results for Bezuclastinib in Nonadvanced Systemic Mastocytosis at SUMMIT Trial, Prepares for NDA Submission - Quiver Quantitative
Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematology (ASH) - The Manila Times
Tema Etfs LLC Has $845,000 Holdings in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences Inc. (COGT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Cogent Biosciences, Inc. $COGT is Saturn V Capital Management LP's 5th Largest Position - MarketBeat
Cogent Biosciences, Inc. (NASDAQ:COGT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Is Cogent Biosciences Inc a good long term investmentREITs Market Trends & Free Exceptional ROI Methods - earlytimes.in
Can Cogent Biosciences Inc. stock deliver consistent earnings growthJuly 2025 Technicals & High Conviction Buy Zone Alerts - Newser
Stock Traders Buy Large Volume of Cogent Biosciences Call Options (NASDAQ:COGT) - MarketBeat
XTX Topco Ltd Has $836,000 Stock Position in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences (COGT) Stock Analysis Report | Financials & Insights - Benzinga
Virtus Investment Advisers LLC Has $94,000 Stock Position in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences (COGT) Price Target Increased by 93.94% to 43.52 - MSN
Geode Capital Management LLC Raises Stake in Cogent Biosciences, Inc. $COGT - MarketBeat
F m Investments LLC Takes Position in Cogent Biosciences, Inc. $COGT - MarketBeat
Ensign Peak Advisors Inc Grows Position in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences stock hits 52-week high at 40.76 USD By Investing.com - Investing.com Nigeria
Cogent Biosciences stock hits 52-week high at 40.76 USD - Investing.com
Cogent Biosciences Inc (COGT) 財務データ
収益
当期純利益
現金流量
EPS
0.42%
0.32%
大文字化:
|
ボリューム (24 時間):